Spots Global Cancer Trial Database for Compassionate Use Study of Tenalisib (RP6530)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Compassionate Use Study of Tenalisib (RP6530)
Official Title: An Open Label, Compassionate Use Study of Tenalisib (RP6530) in Patients Currently Receiving Treatment on Tenalisib Trials in Hematological Malignancies
Study ID: NCT03711604
Conditions
Interventions
Study Description
Brief Summary: Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, Hellen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Division of Hematology, University of Colorado,, Denver, Colorado, United States
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ltd. M.Zodelava Hematology Centre, Tbilisi, , Georgia
Medivest - Institute of Hematology and Transfusiology, Tbilisi, , Georgia
Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J., Chorzów, , Poland
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
